Biotech Values

[genisi]

I too find ERTs to be one of the most lucrative therapeutic areas; they typically address rare diseases and can have an 'Orphan Drug status'. They have: a high rate of success in the clinic due to a well-understood pathology, straightforward path of intervention, small studies, shorter time to market, small patient market that doesn't require large salesmen force and premium pricing.